Wednesday, 26 April 2017
Latest news
Main » Are Analysts Predicting a Near-Term Upswing For Biogen Idec Inc. (NASDAQ:BIIB)?

Are Analysts Predicting a Near-Term Upswing For Biogen Idec Inc. (NASDAQ:BIIB)?

31 January 2017

On the company's financial health, Biogen Inc reported $5.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Jan 26, 2017. Risks to achieving Target Price / Valuation: Regeneron Pharmaceuticals - REGN Regeneron's revenues and/or EPS may fall below our estimates, resulting in downside to our target price. Most recently, in October 2015, Alexander Denner, a Director at BIIB bought 310,000 shares for a total of $86,015,000.

12/16/2016 - Cantor Fitzgerald began new coverage on Biogen Idec Inc. giving the company a " rating.

Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $338.67, representing a 21.7% upside. Biogen presently has an average rating of "Buy" and an average price target of $332.75. The Hedge Fund company now holds 2,644 shares of BIIB which is valued at $723,980.

01/17/2017 - Biogen Idec Inc. had its " rating reiterated by analysts at BMO Capital Markets. The mean consensus price target now stands at $333.142.

Boasting a price of $276.06, Biogen Inc (NASDAQ:BIIB) traded -0.77% lower on the day. Northern Trust Corp now owns 2,978,479 shares of the biotechnology company's stock worth $932,354,000 after buying an additional 12,483 shares during the last quarter. Biogen has a 52 week low of $223.02 and a 52 week high of $333.65.

The stock's 50 day moving average is 285.37 and its 200 day moving average is 297.82. The stock's market capitalization is 59.79B. Biogen Inc makes up approx 0.10% of Raymond James Trust N.a.'s portfolio.Hills Bank Trust Co boosted its stake in BIIB in the latest quarter, The investment management firm added 254 additional shares and now holds a total of 4,564 shares of Biogen Inc which is valued at $1,291,658. Biogen had a return on equity of 40.02% and a net margin of 34.03%. The firm earned $2.96 billion during the quarter, compared to the consensus estimate of $2.91 billion. During the same quarter in the previous year, the company posted $4.50 EPS. The firm's quarterly revenue was up 1.2% on a year-over-year basis.

Based on the latest notes released to investors, 8 analysts have issued a rating of "buy", 8 analysts "outperform", 9 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Baystate Wealth Management LLC now owns 1,019 shares of the biotechnology company's stock valued at $319,000 after buying an additional 5 shares during the last quarter. Norway Savings Bank purchased a new stake in Biogen during the fourth quarter valued at $484,000. It would take about 1.24 days to cover all short positions. Buckingham Asset Management LLC now owns 865 shares of the biotechnology company's stock valued at $209,000 after buying an additional 15 shares during the last quarter. Finally, Woodstock Corp increased its position in Biogen by 0.6% in the third quarter. The company's shares closed last Friday at $278.21. The correct version of this article can be read at https://www.com-unik.info/2017/01/31/jefferies-group-weighs-in-on-biogen-inc-s-q2-2017-earnings-biib.html. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment.